Scorpius Holdings, Inc.

Equities

SCPX

US42237K4094

Pharmaceuticals

Market Closed - Nyse 04:10:00 2024-04-18 pm EDT 5-day change 1st Jan Change
0.1586 USD -1.06% Intraday chart for Scorpius Holdings, Inc. -0.88% -63.98%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : Focus Turns to -2- DJ
US Stock Futures Flat Ahead of Powell Speech After Reaching Record Highs on Thursday MT
Scorpius Holdings, Inc. Wins Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University CI
Scorpius Closes $1.5 Million Public Offering MT
Scorpius Holdings Prices Stock Offering at $0.15 a Share MT
Scorpius Holdings, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023 CI
NightHawk Biosciences, Inc. will Change its Name to Scorpius Holdings, Inc CI
Nighthawk Biosciences, Inc. Announces the Promotion of Joe Payne to President and Chief Operating Officer of Its Scorpius Biomanufacturing Subsidiary CI
NightHawk?s Scorpius BioManufacturing Subsidiary Receives Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program CI
NightHawk Biosciences Postpones Planned Name Change MT
Nighthawk?S Scorpius Biomanufacturing Subsidiary Commences Work on Preclinical Program for New Client CI
NightHawk Biosciences, Inc. Announces Executive Appointments CI
NightHawk Biosciences, Inc. has Changed its Ticker to SCPX from NHWK CI
Scorpius BioManufacturing Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement for A Leading National University CI
Jeffrey Wolf acquired Elusys Therapeutics, Inc. from NightHawk Biosciences, Inc.. CI
NightHawk Biosciences, Inc. announced that it expects to receive $2.25 million in funding CI
NightHawk Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Jeffrey Wolf submitted a preliminary, non-binding offer letter to acquire Elusys Therapeutics, Inc. from NightHawk Biosciences, Inc. for $40.5 million. CI
NightHawk Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
NightHawk Biosciences, Inc.(NYSEAM:NHWK) dropped from Russell Microcap Value Index CI
NightHawk Biosciences, Inc.(NYSEAM:NHWK) dropped from Russell 3000E Value Index CI
NightHawk Biosciences, Inc.(NYSEAM:NHWK) dropped from Russell 3000E Index CI
NightHawk Biosciences, Inc.(NYSEAM:NHWK) dropped from Russell Microcap Index CI
NightHawk Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Chart Scorpius Holdings, Inc.
More charts
Scorpius Holdings, Inc., formerly NightHawk Biosciences, Inc., is an integrated contract development and manufacturing company. The Company is focused on advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. Its analytical services include development of a comprehensive range of analytical test methods to characterize complex biologics, including cell therapy-based products, protein therapeutics, vaccines and advanced therapies. Its Clinical Biomanufacturing includes cGMP Mammalian Cell Culture, and cGMP Microbial Fermentation. Its San Antonio facility is focused on the commercial-scale manufacturing of biodefense-focused molecules and biologics therapeutics. Its biomanufacturing services focus on accelerating product development timelines from pre-clinical evaluation to first-in-human studies.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.1586 USD
Average target price
10 USD
Spread / Average Target
+6,205.17%
Consensus
  1. Stock Market
  2. Equities
  3. SCPX Stock
  4. News Scorpius Holdings, Inc.
  5. Alliance Global Adjusts Heat Biologics' Price Target to $15.50 From $20, Reiterates Buy Rating